Cargando…

Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data

Sphingosine 1-phosphate (S1P) receptors are bioactive lipid metabolites that bind five different types of receptors expressed ubiquitously in human body and mediate a broad range of biological functions. Targeting S1P receptors is nowadays a well-established pharmacological strategy to treat multipl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruggieri, Serena, Quartuccio, Maria Esmeralda, Prosperini, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958267/ https://www.ncbi.nlm.nih.gov/pubmed/35356493 http://dx.doi.org/10.2147/DNND.S313825

Ejemplares similares

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Correction: oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
Publicado: (2019)

An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis
por: Valenzuela, Belén, et al.
Publicado: (2022)

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
por: Kappos, Ludwig, et al.
Publicado: (2021)

Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies
por: Freedman, Mark S., et al.
Publicado: (2022)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

Lesion symptom map of cognitive–postural interference in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2017)

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2014)

Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies
por: Prosperini, Luca, et al.
Publicado: (2022)

Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies
por: Prosperini, Luca, et al.
Publicado: (2021)

Increased risk of death from COVID-19 in multiple sclerosis: A meta-analysis of observational studies
por: Prosperini, Luca, et al.
Publicado: (2021)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
por: Furneri, Gianluca, et al.
Publicado: (2019)

The Clinical Relevance of Force Platform Measures in Multiple Sclerosis: A Review
por: Prosperini, Luca, et al.
Publicado: (2013)

The added value of spinal cord lesions to disability accrual in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2023)

A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2020)

Spotlight on postural control in patients with multiple sclerosis
por: Prosperini, Luca, et al.
Publicado: (2018)

Therapeutic Use of a Selective S1P(1) Receptor Modulator Ponesimod in Autoimmune Diabetes
por: You, Sylvaine, et al.
Publicado: (2013)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases
por: Nistri, Riccardo, et al.
Publicado: (2021)

Effects of multiple-dose ponesimod, a selective S1P(1) receptor modulator, on lymphocyte subsets in healthy humans
por: Jurcevic, Stipo, et al.
Publicado: (2016)

Biocomparison of Three Formulations of the S1P(1) Receptor Modulator Ponesimod in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2015)

Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
por: Hauer, Larissa, et al.
Publicado: (2022)

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
por: Ruggieri, Serena, et al.
Publicado: (2023)

Identifying responders and nonresponders to interferon therapy in multiple sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
por: Prosperini, Luca, et al.
Publicado: (2016)

Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
por: Miller, Aaron E.
Publicado: (2017)

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2021)

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Jankovic, Slobodan M
Publicado: (2010)

Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)
por: Berger, Amnon A., et al.
Publicado: (2021)

Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse
por: Mills, Elizabeth A., et al.
Publicado: (2017)

Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
por: Castillo-Trivino, Tamara, et al.
Publicado: (2013)

The Synergistic Anti-Apoptosis Effects of Amniotic Epithelial Stem Cell Conditioned Medium and Ponesimod on the Oligodendrocyte Cells
por: Safaeinejad, Fahimeh, et al.
Publicado: (2021)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
por: Dumitrescu, Laura, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4fg90tj5n3a8ku922n0qqrdj4d